Bio Pharma Dive
JULY 28, 2023
The British pharma is deepening its investment in genetic medicine through a deal for a group of Pfizer’s gene therapy delivery tools, while the New York giant cuts back.
Pharmaceutical Technology
JULY 28, 2023
NS Pharma’s candidate would be the first to target Duchenne Muscular Dystrophy (DMD) patients amenable to exon 44 skipping therapy.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Rethinking Clinical Trials
JULY 27, 2023
Leaders of the NIH Pragmatic Trials Collaboratory hosted an onboarding meeting for the program’s 3 newest Demonstration Projects. The projects joined the program under the UG3 cooperative agreement mechanism to support a 1-year planning phase in preparation for potential transition to a UH3 implementation phase. Access the complete materials from the onboarding session.
Pharma Times
JULY 27, 2023
New HSCC document deems the UK’s vaccination position to be at risk - News - PharmaTimes
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
JULY 28, 2023
The company will lay off 87% of its workforce and halt further research, including for a gene editing therapy to treat the rare disease PKU.
Pharmaceutical Technology
JULY 25, 2023
Boehringer Ingelheim and Eli Lilly have secured approval from the EC for Jardiance to treat adults with chronic kidney disease (CKD).
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharma Times
JULY 25, 2023
The company will utilise Qureight’s AI technology to undergo studies across a variety of complex lung diseases - News - PharmaTimes
Bio Pharma Dive
JULY 28, 2023
The deal is a major bet by Biogen and its new CEO Chris Viehbacher, who’s reorganized R&D, cut costs and laid off staff since becoming company head last year.
Pharmaceutical Technology
JULY 24, 2023
Verrica has received approval from the US FDA for its YCANTH to treat molluscum in adult and paediatric patients aged two years and above.
Fierce Pharma
JULY 28, 2023
On Monday during a quarterly earnings call, when Biogen CEO Chris Viehbacher was asked about the company’s potential to execute M&A, he randomly offered “we’ve got, I think, about $7.3 billion | Biogen has revealed a proposal to acquire Reata Pharmaceuticals for $7.3 billion. The Texas-based rare disease specialist brings newly approved Skyclarys, the first treatment for the neurologic disorder Friedreich’s ataxia with peak sales potential of $1.5 billion.
Pharma Times
JULY 26, 2023
The advice includes a national rollout of the HCV GP champion programme and further testing - News - PharmaTimes
Bio Pharma Dive
JULY 26, 2023
The companies are enrolling people with melanoma in a Phase 3 trial aimed at testing whether the shot can prevent disease recurrence.
Pharmaceutical Technology
JULY 26, 2023
Eli Lilly has extended the tender offer expiration date for the acquisition of all Dice Therapeutics in a deal valued at $2.4bn.
pharmaphorum
JULY 28, 2023
1000Farmacie Secures $25 Million in Series A Funding Nicole.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharma Times
JULY 26, 2023
The new company’s core mission is to boost patient access to disease-modifying treatments - News - PharmaTimes
Bio Pharma Dive
JULY 27, 2023
GSK expects its respiratory syncytial virus vaccine will be a multibillion dollar product. But at the beginning it’s predicting a slower launch than for its fast-selling shingles shot.
Pharmaceutical Technology
JULY 24, 2023
Shares in the company dropped by 29% despite assurances the failure would not harm its 2023 financial outlook.
Pharmaceutical Commerce
JULY 28, 2023
CDMO’s Turku addition will span over 69,000 square feet and support the production of ATMPs.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Pharma Times
JULY 27, 2023
OCTP aims to demonstrate the lead candidate’s safety, tolerability and pharmacokinetic profile - News - PharmaTimes
Bio Pharma Dive
JULY 24, 2023
The shot failed to meet a key goal of Bavarian Nordic’s Phase 3 study, a finding that separates it from marketed vaccines developed by Pfizer and GSK.
Pharmaceutical Technology
JULY 27, 2023
GSK has reported an adjusted operating profit of £2.17bn in Q2 2023, which is an almost 8% increase from the £2.
Drug Patent Watch
JULY 28, 2023
Annual Drug Patent Expirations for SYMBICORT Symbicort is a drug marketed by Astrazeneca and is included in one NDA. It is available from three suppliers. There are eleven patents protecting… The post New patent expiration for Astrazeneca drug SYMBICORT appeared first on DrugPatentWatch - Make Better Decisions.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
Pharma Times
JULY 28, 2023
Mage Biologics aims to progress a novel, orally administered monoclonal antibody - News - PharmaTimes
Bio Pharma Dive
JULY 24, 2023
Regulators are recognizing mass spectrometry as a powerful tool in Host Cell Protein analysis. Are you ready to implement HCP-MS?
Pharmaceutical Technology
JULY 28, 2023
Senator Bernie Sanders has proposed price caps on drugs developed with federal funds, following a political career battling against high drug prices.
pharmaphorum
JULY 28, 2023
Merck's challenge to Pfizer's Prevnar grows Phil.
Pharma Times
JULY 25, 2023
The CB307 study expansion involves the addition of a new pembrolizumab combination cohort - News - PharmaTimes
Bio Pharma Dive
JULY 24, 2023
Outsourcing in the cell and gene therapy industry is booming and no longer considered just a “trend.
Pharmaceutical Technology
JULY 28, 2023
As several economies deal with inflation, there has been a reduction in deals involving contract manufacturing organisations.
pharmaphorum
JULY 28, 2023
After cutbacks, Biogen adds new drug with $7.3bn Reata buy Phil.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Expert insights. Personalized for you.
246 
Let's personalize your content